World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
122
Citations
71515
World Ranking
3421
National Ranking
1884

Overview

Julio Rosenstock is affiliated with The University of Texas Southwestern Medical Center in the United States. Their research predominantly focuses on the field of medicine, with a substantial emphasis on endocrinology, diabetes, and metabolism. Rosenstock's scholarly contributions cover various subfields including molecular biology, surgery, cardiology and cardiovascular medicine, and pharmacology.

The main topics explored in their research include:

  • Diabetes Treatment and Management
  • Diabetes Management and Research
  • Metabolism, Diabetes, and Cancer
  • Pancreatic function and diabetes
  • Pharmacology and Obesity Treatment
  • Diabetes and associated disorders
  • Cardiovascular Function and Risk Factors

Rosenstock has coauthored extensively with several researchers, among the most frequent collaborators are:

  • Stefano Del Prato
  • Juan P. Frías
  • Vivian Fonseca
  • Melanie J. Davies
  • Ildiko Lingvay

The researcher's work has been published in a range of scientific journals, with recurrent contributions to:

  • Diabetes Obesity and Metabolism
  • Diabetes
  • Diabetologie und Stoffwechsel
  • Diabetes Care
  • New England Journal of Medicine

Some recent papers authored or coauthored by Julio Rosenstock include:

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021, New England Journal of Medicine)
  • Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021, New England Journal of Medicine)
  • Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials (2021, The Lancet Diabetes & Endocrinology)
  • Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial (2021, The Lancet)
  • Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (2021, JAMA)

The scope of Rosenstock's research reflects an interdisciplinary approach that integrates diabetes management, obesity treatment, and cardiovascular health through clinical trials and meta-analyses. Their prolific publication record includes over 500 works in medicine, with a significant quantity focused specifically on endocrinology and metabolism topics related to diabetes.

Best Publications

  • Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

    Steven P. Marso;Stephen C. Bain;Agostino Consoli;Freddy G. Eliaschewitz

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity.

    John P.H. Wilding;Rachel L. Batterham;Rachel L. Batterham;Salvatore Calanna;Melanie Davies

  • The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

    Matthew C. Riddle;Julio Rosenstock;John Gerich

  • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

    John B Buse;Julio Rosenstock;Giorgio Sesti;Wolfgang E Schmidt

  • Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

    David M. Kendall;Matthew C. Riddle;Julio Rosenstock;Dongliang Zhuang

  • Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial

    F. Xavier Pi-Sunyer;Louis J. Aronne;Hassan M. Heshmati;Jeanne Devin

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    Juan P. Frías;Melanie J. Davies;Julio Rosenstock;Federico C. Pérez Manghi

  • Glimepiride, a New Once-Daily Sulfonylurea: A double-blind placebo-controlled study of NIDDM patients

    Julio Rosenstock;Ellis Samols;Douglas B. Muchmore;Jill Schneider

  • Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.

    Julio Rosenstock;Michael Tuchman;Linda LaMoreaux;Uma Sharma

  • Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

    Vivian Fonseca;Julio Rosenstock;Rita Patwardhan;Alan Salzman

  • Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

    Naveed Sattar;Matthew M Y Lee;Søren L Kristensen;Kelley R H Branch

  • Basal Insulin Therapy in Type 2 Diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

    Julio Rosenstock;Sherwyn L. Schwartz;Charles M. Clark;Glen D. Park

  • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Julio Rosenstock;Ronald Brazg;Paula J Andryuk;Kaifeng Lu

  • Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

    Julio Rosenstock;Ele Ferrannini

  • Reduced Hypoglycemia Risk With Insulin Glargine A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

    Julio Rosenstock;George Dailey;Massimo Massi-Benedetti;Andreas Fritsche

  • Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

    Melanie Davies;Louise Færch;Ole K Jeppesen;Arash Pakseresht

  • Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial

    Guntram Schernthaner;Jorge Luiz Gross;Julio Rosenstock;Michael Guarisco

  • Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

    Domenica Rubino;Niclas Abrahamsson;Melanie Davies;Melanie Davies;Dan Hesse

  • Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

    John B Buse;Richard M Bergenstal;Leonard C Glass;Cory R Heilmann

Frequent Co-Authors

Geremia B. Bolli
Geremia B. Bolli University of Perugia
Bernard Zinman
Bernard Zinman University of Toronto
Vivian Fonseca
Vivian Fonseca Tulane University
John B. Buse
John B. Buse University of North Carolina at Chapel Hill
Hans-Juergen Woerle
Hans-Juergen Woerle Nestlé (Switzerland)
Melanie J. Davies
Melanie J. Davies University of Leicester
Nikolaus Marx
Nikolaus Marx RWTH Aachen University
Darren K. McGuire
Darren K. McGuire The University of Texas Southwestern Medical Center
Robert R. Henry
Robert R. Henry University of California, San Diego
William T. Cefalu
William T. Cefalu National Institute of Diabetes and Digestive and Kidney Diseases

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school, several online degree pathways can expand your expertise and open diverse opportunities. Many professionals pursue advanced healthcare management degrees to move into leadership roles. Consider enrolling in one of the top online MHA programs that are CAHME accredited for a flexible, high-quality education in administration.

Nurses seeking career advancement without the need for additional clinical hours can explore online RN to BSN no clinicals programs. These offerings are ideal for working RNs who want to earn their bachelor's degree efficiently and conveniently.

If you aim for the highest levels of clinical practice, doctoral programs are available entirely online. Options like accelerated DNP programs online let experienced nurses earn a Doctor of Nursing Practice degree in less time. There are also flexible DNP programs designed for various learning preferences and schedules.

Online pathways support career growth while allowing you to balance work and study, making them strong alternatives or complements to traditional medical education in the USA.

Best Scientists Citing Julio Rosenstock

Trending Scientists

Recently Published Articles